{"id":"NCT02993757","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®","officialTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-01","primaryCompletion":"2019-05-27","completion":"2019-05-27","firstPosted":"2016-12-15","resultsPosted":"2020-06-11","lastUpdate":"2022-03-25"},"enrollment":528,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever","Dengue Hemorrhagic Fever","Human Papillomavirus Disease"],"interventions":[{"type":"BIOLOGICAL","name":"CYD Dengue Vaccine","otherNames":["Dengvaxia®"]},{"type":"BIOLOGICAL","name":"CYD Dengue Vaccine","otherNames":["Dengvaxia®"]},{"type":"BIOLOGICAL","name":"Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.","otherNames":["Gardasil®"]}],"arms":[{"label":"CYD Dengue Vaccine + Gardasil (Concomitant Administration)","type":"EXPERIMENTAL"},{"label":"CYD Dengue Vaccine + Gardasil (Sequential Administration)","type":"EXPERIMENTAL"}],"summary":"The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent \\[Types 6, 11, 16, and 18\\] Vaccine, Recombinant) when administered concomitantly or sequentially.\n\nPrimary objectives:\n\n* To demonstrate that the humoral immune response (in terms of geometric mean titers \\[GMTs\\]) to Gardasil after concomitant administration was non-inferior to sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Gardasil.\n* To demonstrate that the humoral immune response to the CYD dengue vaccine after concomitant administration was non-inferior to sequential administration with Gardasil measured 28 days after the last dose of the CYD dengue vaccine.\n\nSecondary Objectives:\n\n* To demonstrate that the humoral immune response (in terms of seroconversion) to Gardasil vaccine after concomitant administration was non-inferior to sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Gardasil.\n* To describe the humoral immune response to Gardasil at baseline and after each dose of Gardasil in each and any group.\n* To describe the humoral immune response to the CYD dengue vaccine at baseline and after each dose of the CYD dengue vaccine in each and any group.\n* To describe the safety of Gardasil and the CYD dengue vaccine after each and any dose in each group.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) Against Each Gardasil Vaccine Human Papillomavirus (HPV) Antigen (HPV-6, HPV-11, HPV-16, HPV-18) 28 Days After Last Gardasil Vaccination in the Previously Dengue Immune Participants","timeFrame":"28 days after the last Gardasil vaccination","effectByArm":[{"arm":"CYD Dengue Vaccine + Gardasil (Concomitant Administration)","deltaMin":420,"sd":null},{"arm":"CYD Dengue Vaccine + Gardasil (Sequential Administration)","deltaMin":428,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":5,"countries":["Malaysia"]},"refs":{"pmids":["34250977"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":263},"commonTop":["Injection Site Pain","Myalgia","Headache","Asthenia","Malaise"]}}